101
|
Casali MB, Blandino A, Del Sordo S, Vignali G, Novello S, Travaini G, Berlusconi M, Genovese U. Alleged malpractice in orthopaedics. Analysis of a series of medmal insurance claims. J Orthop Traumatol 2018; 19:7. [PMID: 30112637 PMCID: PMC6093819 DOI: 10.1186/s10195-018-0500-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 01/23/2018] [Indexed: 11/29/2022] Open
Abstract
Background Medical malpractice is an important topic worldwide, and orthopedics is a clinical branch that is considered to be at a high risk for claims. The analysis of a series of medmal insurance claims allows forensic pathologists, clinicians, and insurance companies to probe the risk of a specific clinical branch for medical malpractice claims and highlights areas where care may be improved. We investigated the main features of a major Italian insurance broker’s archive in order to identify recurrent pitfalls in this field. Materials and methods A retrospective study was carried out on orthopedics claims. The archive covered claims from 2002 to 2013 that targeted 1980 orthopedists. Results 635 claims were found and analyzed with a focus on the clinical activity invocked in the claim, the presence of alleged team malpractice, the clinical outcome of the case, and the final forensic decision regarding the claim. 299 orthopedists had at least one malpractice claim made against them during the available period; 146 orthopedists were subject to more than one malpractice claim. Most of the claims regarded perioperative and operative cases, usually originating from civil litigation. The anatomical sites most commonly involved were the hip or knees, and sciatic nerve lesions were the main contributor. Conclusions Orthopedics is a medical specialty with a high risk for malpractice claims. In our study, medical malpractice was observed in nearly 50% of the cases—typically in surgery-linked cases resulting in permanent impairment of the patient. Death from orthopedics malpractice seemed to be rare. Level of Evidence IV.
Collapse
|
102
|
Fornaro M, Iasevoli F, Novello S, Fusco A, Anastasia A, De Berardis D, Valchera A, de Bartolomeis A. Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. J Affect Disord 2018; 228:118-124. [PMID: 29245092 DOI: 10.1016/j.jad.2017.12.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 11/08/2017] [Accepted: 12/05/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Hospitalization accounts for significant health care resource utilization for treatment-resistant Bipolar Disorder (BD), especially among frequent users of acute inpatient psychiatric units. Appraisal of the clinical features and predictive role of selected variables is therefore crucial in such population, representing the aim of the present research. METHODS A hundred and nineteen BD inpatients with an established history of pharmacological treatment resistance for either mania or bipolar depression were classified as long hospitalization cases (LOS+) and their controls and compared against each other for a number of demographic, clinical, and psychopathological features. RESULTS Overall, female sex, current second-generation atypical antipsychotic (SGA)/mood stabilizer other than lithium as well as antidepressant treatment at the admission occurred statistically more frequently among LOS+ cases, concordant with higher scores at the Hamilton scales for depression and anxiety. Lithium utilization at the time of hospitalization did not differ between cases and controls (LOS-, n = 81/119), as predominant affective temperament and other psychopathological rating did not. Overall, the time of admission, use of SGA, anticonvulsant (other than lithium), antidepressant, lifetime alcohol dependence, and BD Type (-I or -II), but not current mood polarity at the time of hospitalization, correctly predicted LOS+ grouping 68.2% of the times: Exp(B) = 3.151, p042. LIMITATIONS Post-hoc, cross-sectional study, relatively small sample size, recall and selection bias on some diagnoses. CONCLUSIONS Overall, LOS+ treatment-resistant BD inpatients characterize for higher severity and greater pharmaco-utilization use, which warrants replication studies to include additional predictors to shed further light on the matter.
Collapse
|
103
|
Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M. Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists. Br J Pharmacol 2018; 175:782-796. [PMID: 29232769 DOI: 10.1111/bph.14123] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Revised: 11/21/2017] [Accepted: 11/26/2017] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND AND PURPOSE We previously showed that nociceptin/orphanin FQ opioid peptide (NOP) receptor agonists attenuate the expression of levodopa-induced dyskinesia in animal models of Parkinson's disease. We now investigate the efficacy of two novel, potent and chemically distinct NOP receptor agonists, AT-390 and AT-403, to improve Parkinsonian disabilities and attenuate dyskinesia development and expression. EXPERIMENTAL APPROACH Binding affinity and functional efficacy of AT-390 and AT-403 at the opioid receptors were determined in radioligand displacement assays and in GTPγS binding assays respectively, conducted in CHO cells. Their anti-Parkinsonian activity was evaluated in 6-hydroxydopamine hemi-lesioned rats whereas the anti-dyskinetic properties were assessed in 6-hydroxydopamine hemi-lesioned rats chronically treated with levodopa. The ability of AT-403 to inhibit the D1 receptor-induced phosphorylation of striatal ERK was investigated. KEY RESULTS AT-390 and AT-403 selectively improved akinesia at low doses and disrupted global motor activity at higher doses. AT-403 palliated dyskinesia expression without causing sedation in a narrow therapeutic window, whereas AT-390 delayed the appearance of abnormal involuntary movements and increased their duration at doses causing sedation. AT-403 did not prevent the priming to levodopa, although it significantly inhibited dyskinesia on the first day of administration. AT-403 reduced the ERK phosphorylation induced by SKF38393 in vitro and by levodopa in vivo. CONCLUSIONS AND IMPLICATIONS NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation. The therapeutic window, however, varies across compounds. AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.
Collapse
|
104
|
Morari M, Brugnoli A, Pisanò CA, Novello S, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. J Pharmacol Exp Ther 2017; 364:198-206. [DOI: 10.1124/jpet.117.245100] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Accepted: 11/15/2017] [Indexed: 12/13/2022] Open
|
105
|
Riganti C, Pradotto M, Righi L, Marchiò C, Capelletto E, Buttigliero C, Costardi L, Kopecka J, Bironzo P, Ruffini E, Novello S, Scagliotti G. P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
106
|
Novello S, Nowak A, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sorensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, Von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
107
|
Bafunno D, Galetta D, Biglia C, Catino A, Ferraresi F, Lapadula V, Leo S, Logroscino A, Miccianza A, Misino A, Montagna E, Pacchiana M, Petrillo P, Pizzutilo P, Rapetti S, Ricci D, Novello S. P3.06-003 What Do the Children Think about Smoking and How Are They Helped in Prevention? J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
108
|
Nowak A, Grosso F, Steele N, Novello S, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sørensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti G. MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.636] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
109
|
Yang J, Reckamp K, Kim Y, Novello S, Smit E, Lee J, Su W, Akerley W, Blakely C, Bazhenova L, Chiari R, Hsia T, Golsorkhi T, Despain D, Shih D, Rolfe L, Popat S, Wakelee H. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.11.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
110
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, De Marinis F, Minuti G, Buosi R, Morabito A, Spitaleri G, Gridelli C, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Alì G, Proietti A, Fontanini G, Joseph A, Crinò L, Cappuzzo F. P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
111
|
Mazieres J, Novello S, De Castro J, Migliorino M, Helland Å, Dziadziuszko R, Griesinger F, Wolf J, Zeaiter A, Cardona A, Balas B, Karagiannis T, Chlistalla M, Smoljanovic V, Oh I. P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.667] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
112
|
Capelletto E, Pacchiana M, De Luca E, Reale M, Gianetta M, Novello S. P1.04-002 Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
113
|
Carnio S, Galetta D, Scotti V, Cortinovis D, Antonuzzo A, Pisconti S, Rossi A, Martelli O, Cecere F, Lunghi A, Del Conte A, Montagna E, Topulli J, Pelizzoni D, Rapetti S, Gianetta M, Pacchiana M, Pegoraro V, Cataldo N, Bria E, Novello S. The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
114
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, de Marinis F, Minuti G, Buosi R, Morabito A, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Fontanini G, Crinò L, Cappuzzo F. Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
115
|
Reck M, Paz-Ares L, Pérol M, Johnson M, Pennell N, Novello S, Cappuzzo F, Bidoli P, Zimmermann A, Lee P, Sashegyi A, Varea Menendez R. Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
116
|
Mele T, Cottino F, Busso M, Sardo D, Guerrera F, Costardi L, Ruffini E, Maletta F, Righi L, Vatrano S, Volante M, Scagliotti G, Novello S, Trusolino L. Prospective generation of PDTX (patient derived tumor xenografts) and molecular profiling of NSCLC (non small cell lung cancer). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
117
|
Gobbini E, Reale M, De Luca E, Righi L, Gianetta M, Capelletto E, Buffoni L, Giaj Levra M, Novello S. DNA amount comparison between cytologic and histologic samples for epithelial growth factor receptor (EGFR) testing in non-small-cell lung cancer (NSCLC) patients: a single institution experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
118
|
Pilotto S, Simbolo M, Gkountakos A, Mafficini A, Vicentini C, Sperduti I, Ludovini V, Chiari R, Novello S, Milella M, Carbognin L, Caregnato E, Santo A, Infante M, Brunelli M, Corbo V, Scarpa A, Tortora G, Bria E. Results of an integrated multi-platforms analysis in squamous cell lung carcinoma (SqCLC) revealed PI3K/RICTOR-mTORC2 axis as a potential prognostic biomarker and druggable target. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
119
|
Rapetti S, Biglia C, Capelletto E, Galetta D, Baffunno D, Binato S, Marchese F, Ferraresi F, Novello S. Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx433.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
120
|
Grosso F, Ceresoli G, Roveta A, Bearz A, Valentino F, Novello S, Santoro A, Cognetti F, Amadori D, Dall'olio F, Zucchi L, Pastorino U, Rea F, Boni C, Maggioni P, Gallizzi G, Maconi A, Scagliotti G, Magnani C. Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
121
|
Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino M, Helland A, Dziadziuszko R, Griesinger F, Kotb A, Zeiter A, Cardona A, Balas B, Johannsdottir H, Das-Gupta A, Wolf J. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.058] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
122
|
Pilotto S, Simbolo M, Gkountakos A, Vicentini C, Sperduti I, Ludovini V, Chiari R, Novello S, Milella M, Mafficini A, Carbognin L, Caregnato E, Santo A, Infante M, Brunelli M, Corbo V, Scarpa A, Tortora G, Bria E. PI3K/RICTOR-mTORC2 axis as a driver of prognosis and potential druggable target in squamous cell lung carcinoma (SqCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
123
|
de Castro J, Novello S, Mazieres J, Oh IJ, Migliorino M, Helland A, Dziadziuszko R, Griesinger F, de Marinis F, Zeaiter A, Cardona A, Balas B, Johannsdottir H, Chlistalla M, Smoljanovic V, Wolf J. CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.048] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
124
|
Giaj Levra M, Menis J, Luciani A, De Maio E, Hasan B, Berghmans T, Massiani M, De Waele M, Dingemans AM, Donckele J, Faivre-Finn C, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Tryfonidis K, Wildiers H, Besse B, Novello S. Diagnostic and therapeutic strategies for elderly patients with advanced non-small cell lung cancer (NSCLC): Results from an EORTC pan-European survey. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
125
|
Novello S, Nowak A, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sorensen J, Planchard D, Ceresoli G, Hughes B, Mazieres J, Socinski M, von Wangenheim U, Barrueco J, Morsli N, Scagliotti G. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|